Adjuvant endocrine therapy for premenopausal women with breast cancer: Patient adherence and physician prescribing practices in Mexico

被引:5
|
作者
Villarreal-Garza, Cynthia [1 ,2 ]
Mesa-Chavez, Fernanda [1 ,2 ]
Ferrigno, Ana S. [1 ,2 ]
Garza-Ramos, Cynthia De la [1 ,2 ]
Fonseca, Alan [2 ,3 ]
Villanueva-Tamez, Karen [1 ]
Campos-Salgado, Jose Y. [3 ]
Cruz-Ramos, Marlid [2 ,3 ]
Rodriguez-Gomez, David O. [1 ]
Ruiz-Cruz, Sandy [3 ]
Cabrera-Galeana, Paula [3 ]
机构
[1] Tecnol Monterrey, Hosp Zambrano Hell TecSalud, Breast Canc Ctr, Batallon San Patricio 112,14th Floor, San Pedro Garza Garcia 66278, Nuevo Leon, Mexico
[2] Joven & Fuerte Programa Atenc & Invest Mujeres Jo, Holbein 227,Int 210AB, Mexico City 03720, DF, Mexico
[3] Inst Nacl Cancerol, Dept Tumores Mamarios & Invest, San Fernando 22,Belisario Dominguez Secc 16, Mexico City 14080, DF, Mexico
来源
BREAST | 2021年 / 59卷
关键词
Breast cancer; Endocrine therapy; Adherence; Premenopausal; Prescribing practices; Mexico; CLINICAL-PRACTICE GUIDELINES; HORMONAL-THERAPY; EARLY DISCONTINUATION; OVARIAN SUPPRESSION; TAMOXIFEN; NONADHERENCE; COHORT; SURVIVORS; PERSPECTIVES; PERSISTENCE;
D O I
10.1016/j.breast.2021.05.013
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: In resource-constrained settings, data regarding breast cancer patients' adherence to endocrine therapy (ET) and physicians' prescribing practices is limited. This study aims to decrease this knowledge gap in a real-world clinical practice. Methods: Premenopausal women with stage 0-III hormone-sensitive breast cancer and receiving adjuvant ET during the past 1-5 years were identified in three Mexican referral centers. Participants' self reported ET compliance, clinicopathologic characteristics, ET-related knowledge and beliefs, experienced adverse effects, social support, and patient-physician relationships were evaluated. Physician ET prescribing practices were compared with the gold standard according to international and national guidelines to assess clinicians' adherence to standard-of-care prescription. Results: In total, 95/132 (72%) and 35/132 (27%) participants reported complete and acceptable adherence, respectively. Incomplete adherence was mainly attributed to forgetfulness, adverse effects, and unwillingness to take ET. Being employed/studying (p = 0.042), worrying about long-term ET use (p = 0.031), and experiencing >7 ET-related symptoms (p = 0.018) were associated with incomplete adherence. Guideline-endorsed regimens were prescribed in 84/132 (64%) patients, while the rest should have undergone ovarian function suppression (OFS) but instead received tamoxifen monotherapy. Conclusions: Premenopausal Mexican women self-report remarkably high rates of adequate ET adherence. However, a considerable proportion misses >1 doses/month, usually because of forgetfulness. Notably, only 64% receive standard-of-care ET due to suboptimal prescription of OFS. Interventions that remind patients to take their ET, refine physicians' knowledge on the importance of OFS in high-risk patients, and increase access to OFS could prove pivotal to enhance optimal ET implementation and adherence, which could translate into improved patient outcomes. (c) 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:8 / 15
页数:8
相关论文
共 50 条
  • [41] Chemotherapy-induced amenorrhea and adjuvant endocrine therapy for premenopausal women with early breast cancer
    Rokutanda, N.
    Horiguchi, J.
    Koibuchi, Y.
    Kikuchi, M.
    Nagaoka, R.
    Sato, A.
    Odawara, H.
    Tokiniwa, H.
    Iino, Y.
    Takeyoshi, I.
    EJC SUPPLEMENTS, 2010, 8 (03): : 74 - 74
  • [42] Adherence to Adjuvant Endocrine Therapy in Women With Breast Cancer: A Prospective Observational Study in Japanese Women
    Kuba, Sayaka
    Maeda, Shigeto
    Matsumoto, Megumi
    Yamanouchi, Kosho
    Yano, Hiroshi
    Morita, Michi
    Sakimura, Chika
    Hatachi, Toshiko
    Tokai, Yukiko
    Takatsuki, Mitsuhisa
    Fujioka, Hikaru
    Hayashida, Naomi
    Nagayasu, Takeshi
    Eguchi, Susumu
    CLINICAL BREAST CANCER, 2018, 18 (02) : 150 - 156
  • [43] The role of endocrine therapy in adjuvant management for premenopausal breast cancer patients
    Gornas, Maria
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2005, 9 (08): : 355 - 358
  • [44] Factors Associated With Adjuvant Endocrine Therapy Adherence Among Women With Nonmetastatic Breast Cancer
    Walsh, Leah
    Walsh, Emily
    Hernand, Max
    Antoni, Michael
    Temel, Jennifer
    Greer, Joseph
    Jacobs, Jamie
    PSYCHO-ONCOLOGY, 2024, 33
  • [45] Which Is the Appropriate Adjuvant Endocrine Therapy for Premenopausal Patients With Breast Cancer?
    Petrelli, Fausto
    Barni, Sandro
    CLINICAL BREAST CANCER, 2015, 15 (03) : 169 - 170
  • [46] Endocrine therapy adherence of premenopausal Mexican breast cancer patients.
    Villarreal-Garza, Cynthia
    Mesa-Chavez, Fernanda
    Sofia Ferrigno, Ana
    De la Garza-Ramos, Cynthia
    Villanueva-Tamez, Karen
    Fonseca, Alan
    Yair Campos-Salgado, Jose
    Pineda, Claudia
    Garcia-Garcia, Marisol
    Omar Rodriguez, David
    Cruz-Ramos, Marlid
    Cabrera-Galeana, Paula
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [47] Endocrinology and hormone therapy in breast cancer - Endocrine therapy in premenopausal women
    Pritchard, K
    BREAST CANCER RESEARCH, 2005, 7 (02) : 70 - 76
  • [48] Endocrinology and hormone therapy in breast cancer: Endocrine therapy in premenopausal women
    Kathleen Pritchard
    Breast Cancer Research, 7
  • [49] The Modern Landscape of Endocrine Therapy for Premenopausal Women with Breast Cancer
    Rossi, Lorenzo
    Pagani, Olivia
    BREAST CARE, 2015, 10 (05) : 312 - 315
  • [50] Optimizing endocrine therapy for premenopausal and postmenopausal women with breast cancer
    Cianfrocca, Mary
    Wolff, Antonio C.
    ONCOLOGY-NEW YORK, 2007, 21 (01): : 63 - 69